There are currently 428 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Breast Cancer, Reasoning, and Activity Intervention
NCT04816006
Recruiting
This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic impact on daily functioning, quality of life, and long-term health. Aerobic exercise has the potential to improve cognitive function and brain health in older adults and is recommended as a safe, tolerable, and accessible... Read More
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Register for Updates
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT03936478
Recruiting
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic rat... Read More
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
07/29/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Breast Cancer, DCIS, LCIS
Register for Updates
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521
Recruiting
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Cancer Center of Kansas, Wichita, Kansas +2 locations
Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Register for Updates
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863
Recruiting
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: HonorHealth Research Institute, Scottsdale, Arizona +12 locations
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Register for Updates
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
NCT06305312
Recruiting
The goal of this study is to evaluate if adding community services navigation to the standard referral process for social needs is an effective and scalable strategy for addressing disparities in follow-up to abnormal breast cancer screening results. The investigators will determine the effectiveness of social needs referrals combined with a community services navigation intervention in the screening mammography setting to improving breast screening outcomes in underserved women.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City, Utah
Conditions: Breast Cancer
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona +18 locations
Conditions: Breast Cancer
Register for Updates
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT05069038
Recruiting
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy. The sensitivity of breast cancer to chemotherapy is often determined by the underlying gene expression pattern and the molecular subtype of the tumor. In addition, not all patients tolerate chemotherapy well. Pre-operative endocrine therapy has emerged as an effective strategy to improve outcomes in patients with early-stage hormo... Read More
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
07/29/2025
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer
Register for Updates
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945
Recruiting
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Mount Sinai Medical Center, Miami Beach, Florida +83 locations
Conditions: Breast Cancer
Register for Updates
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT06176261
Recruiting
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Miami Baptist Cancer Institute/, Miami, Florida +2 locations
Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Register for Updates
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT05064098
Recruiting
This study will assess how patients' long-term quality of life after different surgical approaches compares to their predicted quality of life.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Colorado Hopspital, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
A Study of Language Interpretation Solutions for People With Breast Cancer
NCT06721065
Recruiting
The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey +7 locations
Conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05035836
Recruiting
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, HER2-positive
Register for Updates